vs
Piedmont Realty Trust, Inc.（PDM）与Tarsus Pharmaceuticals, Inc.（TARS）财务数据对比。点击上方公司名可切换其他公司
Tarsus Pharmaceuticals, Inc.的季度营收约是Piedmont Realty Trust, Inc.的1.1倍（$151.7M vs $143.3M），Tarsus Pharmaceuticals, Inc.净利率更高（-5.5% vs -31.4%，领先25.9%），Tarsus Pharmaceuticals, Inc.同比增速更快（128.4% vs 0.4%），过去两年Tarsus Pharmaceuticals, Inc.的营收复合增速更高（134.4% vs 0.0%）
Piedmont Realty Trust是一家公开上市的房地产投资信托（REIT），主要持有、运营和投资美国高增长大都会区的优质写字楼资产，服务科技、专业服务、医疗等多个行业的企业租户，通过战略资产管理和投资组合优化为利益相关方提供稳定长期回报。
Tarsus Pharmaceuticals是一家处于后期临床阶段的生物制药公司，专注于眼科、皮肤科等专科领域创新疗法的研发和商业化，主打产品针对蠕形螨睑缘炎、玫瑰痤疮等未被充分诊断的常见病症，核心市场为美国。
PDM vs TARS — 直观对比
营收规模更大
TARS
是对方的1.1倍
$143.3M
营收增速更快
TARS
高出128.0%
0.4%
净利率更高
TARS
高出25.9%
-31.4%
两年增速更快
TARS
近两年复合增速
0.0%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $143.3M | $151.7M |
| 净利润 | $-45.0M | $-8.4M |
| 毛利率 | — | — |
| 营业利润率 | — | -5.3% |
| 净利率 | -31.4% | -5.5% |
| 营收同比 | 0.4% | 128.4% |
| 净利润同比 | -27.9% | 63.8% |
| 每股收益（稀释后） | $-0.10 | $-0.17 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PDMTARS
| Q1 26 | $143.3M | — | ||
| Q4 25 | $142.9M | $151.7M | ||
| Q3 25 | $139.2M | $118.7M | ||
| Q2 25 | $140.3M | $102.7M | ||
| Q1 25 | $142.7M | $78.3M | ||
| Q4 24 | $143.2M | $66.4M | ||
| Q3 24 | $139.3M | $48.1M | ||
| Q2 24 | $143.3M | $40.8M |
净利润PDMTARS
| Q1 26 | $-45.0M | — | ||
| Q4 25 | $-43.2M | $-8.4M | ||
| Q3 25 | $-13.5M | $-12.6M | ||
| Q2 25 | $-16.8M | $-20.3M | ||
| Q1 25 | $-10.1M | $-25.1M | ||
| Q4 24 | $-30.0M | $-23.1M | ||
| Q3 24 | $-11.5M | $-23.4M | ||
| Q2 24 | $-9.8M | $-33.3M |
营业利润率PDMTARS
| Q1 26 | — | — | ||
| Q4 25 | — | -5.3% | ||
| Q3 25 | — | -12.2% | ||
| Q2 25 | — | -21.6% | ||
| Q1 25 | — | -33.5% | ||
| Q4 24 | — | -36.8% | ||
| Q3 24 | — | -52.3% | ||
| Q2 24 | — | -81.6% |
净利率PDMTARS
| Q1 26 | -31.4% | — | ||
| Q4 25 | -30.3% | -5.5% | ||
| Q3 25 | -9.7% | -10.6% | ||
| Q2 25 | -12.0% | -19.8% | ||
| Q1 25 | -7.1% | -32.1% | ||
| Q4 24 | -20.9% | -34.8% | ||
| Q3 24 | -8.3% | -48.7% | ||
| Q2 24 | -6.8% | -81.6% |
每股收益（稀释后）PDMTARS
| Q1 26 | $-0.10 | — | ||
| Q4 25 | $-0.34 | $-0.17 | ||
| Q3 25 | $-0.11 | $-0.30 | ||
| Q2 25 | $-0.14 | $-0.48 | ||
| Q1 25 | $-0.08 | $-0.64 | ||
| Q4 24 | $-0.25 | $-0.57 | ||
| Q3 24 | $-0.09 | $-0.61 | ||
| Q2 24 | $-0.08 | $-0.88 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $2.3M | $417.3M |
| 总债务越低越好 | — | $72.4M |
| 股东权益账面价值 | $1.5B | $343.4M |
| 总资产 | $4.0B | $562.2M |
| 负债/权益比越低杠杆越低 | — | 0.21× |
8季度趋势，按日历期对齐
现金及短期投资PDMTARS
| Q1 26 | $2.3M | — | ||
| Q4 25 | $731.0K | $417.3M | ||
| Q3 25 | $3.0M | $401.8M | ||
| Q2 25 | $3.3M | $381.1M | ||
| Q1 25 | $2.9M | $407.9M | ||
| Q4 24 | $109.6M | $291.4M | ||
| Q3 24 | $133.6M | $317.0M | ||
| Q2 24 | $138.5M | $323.6M |
总债务PDMTARS
| Q1 26 | — | — | ||
| Q4 25 | $2.2B | $72.4M | ||
| Q3 25 | $2.2B | $72.3M | ||
| Q2 25 | $2.2B | $72.1M | ||
| Q1 25 | $2.2B | $72.0M | ||
| Q4 24 | $2.2B | $71.8M | ||
| Q3 24 | $2.2B | $71.7M | ||
| Q2 24 | $2.2B | $71.6M |
股东权益PDMTARS
| Q1 26 | $1.5B | — | ||
| Q4 25 | $1.5B | $343.4M | ||
| Q3 25 | $1.5B | $335.1M | ||
| Q2 25 | $1.5B | $332.6M | ||
| Q1 25 | $1.6B | $342.5M | ||
| Q4 24 | $1.6B | $224.5M | ||
| Q3 24 | $1.6B | $237.5M | ||
| Q2 24 | $1.7B | $252.2M |
总资产PDMTARS
| Q1 26 | $4.0B | — | ||
| Q4 25 | $4.0B | $562.2M | ||
| Q3 25 | $4.0B | $534.6M | ||
| Q2 25 | $4.0B | $495.0M | ||
| Q1 25 | $4.0B | $500.8M | ||
| Q4 24 | $4.1B | $377.0M | ||
| Q3 24 | $4.1B | $376.3M | ||
| Q2 24 | $4.2B | $376.8M |
负债/权益比PDMTARS
| Q1 26 | — | — | ||
| Q4 25 | 1.49× | 0.21× | ||
| Q3 25 | 1.43× | 0.22× | ||
| Q2 25 | 1.41× | 0.22× | ||
| Q1 25 | 1.40× | 0.21× | ||
| Q4 24 | 1.40× | 0.32× | ||
| Q3 24 | 1.36× | 0.30× | ||
| Q2 24 | 1.34× | 0.28× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $19.3M |
| 自由现金流经营现金流 - 资本支出 | — | $13.0M |
| 自由现金流率自由现金流/营收 | — | 8.6% |
| 资本支出强度资本支出/营收 | 110.3% | 4.2% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-22.3M |
8季度趋势，按日历期对齐
经营现金流PDMTARS
| Q1 26 | — | — | ||
| Q4 25 | $140.6M | $19.3M | ||
| Q3 25 | $35.8M | $18.3M | ||
| Q2 25 | $50.1M | $-29.4M | ||
| Q1 25 | $3.7M | $-20.7M | ||
| Q4 24 | $198.1M | $-22.2M | ||
| Q3 24 | $42.9M | $-8.7M | ||
| Q2 24 | $66.8M | $-14.4M |
自由现金流PDMTARS
| Q1 26 | — | — | ||
| Q4 25 | — | $13.0M | ||
| Q3 25 | — | $16.3M | ||
| Q2 25 | — | $-30.4M | ||
| Q1 25 | — | $-21.2M | ||
| Q4 24 | — | $-22.3M | ||
| Q3 24 | — | $-8.9M | ||
| Q2 24 | — | $-15.4M |
自由现金流率PDMTARS
| Q1 26 | — | — | ||
| Q4 25 | — | 8.6% | ||
| Q3 25 | — | 13.8% | ||
| Q2 25 | — | -29.6% | ||
| Q1 25 | — | -27.1% | ||
| Q4 24 | — | -33.5% | ||
| Q3 24 | — | -18.6% | ||
| Q2 24 | — | -37.8% |
资本支出强度PDMTARS
| Q1 26 | 110.3% | — | ||
| Q4 25 | — | 4.2% | ||
| Q3 25 | — | 1.6% | ||
| Q2 25 | — | 1.0% | ||
| Q1 25 | — | 0.8% | ||
| Q4 24 | — | 0.1% | ||
| Q3 24 | — | 0.6% | ||
| Q2 24 | — | 2.5% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
